| Name | Title | Contact Details |
|---|
Modernizing and simplifying the landscape design and install process. Locally owned and operated in Woodbury, Minnesota. We are the catalyst for your outdoor dream space. OUR STORY Locally established here by 4 high school athletes in 2016. Passionate about making a positive impact in our community. Our expertise, quality, and reliability have helped us continue to grow and serve the residents and businesses of Eastside Twin Cities. Check out our website below for a full list of our services!
A-MAX Auto Insurance is a Texas-based insurance provider founded in 2002, with its headquarters in Dallas. The company specializes in affordable insurance solutions and has rapidly expanded to operate over 200 offices across Texas. In 2022, A-MAX entered the California market by acquiring Sameday Insurance, adding 10 locations in Southern California. A-MAX offers a wide range of insurance products, including auto insurance for cars, motorcycles, boats, RVs, and commercial vehicles. They also provide property insurance for homeowners, renters, and mobile homes, along with specialized services such as SR-22 certificates, Mexico tourist insurance, surety bonds, and notary services. Additionally, A-MAX has commercial solutions, including general liability and commercial auto insurance. The company operates two subsidiaries in Texas: ALPA Auto Insurance and Preferred Coverage Insurance Agency, catering to both non-standard and commercial/personal insurance needs. A-MAX focuses on delivering flexible, customer-centric service to individual consumers and businesses.
FinishWorks is the leading manufacturer and distributor of industrial wood and metal coatings. We are a recognized leader in supplying tailored coating solutions, combining trend-setting finish design with outstanding color consistency. FinishWorks is proud to be an RPM company. RPM International, Inc. (NYSE: RPM) is a global leader in specialty coatings that serves both the industrial and consumer markets.
MedVet is the leading veterinarian owned and led network of specialty and emergency hospitals dedicated to delivering exceptional care and a deeply supportive experience to pets and their loving families, referring veterinarians, and team members. For more than 35 years, MedVets empathetic, insightful, and driven team of expert caregivers has helped the organization grow to be the preferred choice for high quality, compassionate care, proudly serving more than 500,000 patients each year in communities throughout the United States. Our caregivers are deeply committed to MedVets mission of Leading Specialty Healthcare for Pets and our driven by our core values of Teamwork, Leadership, and Compassion. Visit www.medvet.com for further information and to view employment opportunities at MedVet. MedVet is an Equal Opportunity Employer.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.